Previous 10 | Next 10 |
Sundry Photography/iStock Editorial via Getty Images 10x Genomics ([[TXG]] -2.3%) says that its Chromium X series, a next-generation system for single cell analysis, is now commercially available. Chromium X provides routine million cell experiments down to two cents per cell. The system also...
PLEASANTON, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Building on its industry leading position in single cell analysis, 10x Genomics (NASDAQ: TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis. The new Series compr...
PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021. The company’s management will webcast a corresponding conference call begin...
10x Genomics is a global life sciences technology company at the forefront of single-cell sequencing and spatial/temporal genomics. The company has a strong financial position and expects +66% revenue growth in 2021, but the stock trades at an expensive 61.92 P/S. Management predi...
PLEASANTON, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome acros...
USMV is a low volatility fund that often times outperforms during drawdowns, but then significantly underperforms in recoveries. USMV holders are advised to keep on keeping on and not to be too discouraged at the large underperformance. Its constituents are virtually all cash flow...
BNGO is embarking on an ambitious plan to change the lab and diagnostics standards, putting the proceeds of the new equity offering into good use. Although the company achieved high growth in Q1, it stems from a low base, making it hard to justify current price levels, even if the rev...
My last article introduced the holdings and strategy of my long-term portfolio and summarized recent performance. Now, I will provide financial analysis across multiple metrics in a way to understand how the portfolio is performing in both regards to finances and share price. This...
10x Genomics, Inc. is a global life sciences technology company developing innovative biological products from their cross-functional expertise across biology, chemistry, software, and hardware with a broad global customer base. 10x Genomics offers a variety of applications and p...
10x Genomics (NASDAQ: TXG) , which is focused on helping researchers study genomic changes on a cellular level, beat Wall Street expectations in the first quarter, but shares of the company fell substantially. In this video from Motley Fool Live , recorded on May 10 , Fo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...